Risk factors and incidence of long-COVID syndrome in hospitalized patients: does remdesivir have a protective effect?

• Published in: QJM : An International Journal of Medicine Vol. 114; no. 12; pp. 865 - 871
• Main Authors: Boglione, L, Meli, G, Poletti, F, Rostagno, R, Moglia, R, Cantone, M, Esposito, M, Scianguetta, C, Domenicale, B, Di Pasquale, F, Borrè, S
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 09.01.2022
• Subjects: Adenosine Monophosphate - analogs & derivatives; Adenosine Monophosphate - therapeutic use; Alanine - analogs & derivatives; Alanine - therapeutic use; COVID-19 - complications; COVID-19 - drug therapy; Hospitalization; Humans; Incidence; Intensive Care Units; Original Paper; Prospective Studies; Risk Factors; SARS-CoV-2

Summary Background The definition of ‘long-COVID syndrome’ (LCS) is still debated and describes the persistence of symptoms after viral clearance in hospitalized or non-hospitalized patients affected by coronavirus disease 2019 (COVID-19). Aim In this study, we examined the prevalence and the risk f...